LBRX Chief Commercial Officer reports zero beneficial ownership on Form 3

Rhea-AI Filing Summary

LB Pharmaceuticals Inc. (LBRX) reported that its Chief Commercial Officer, listed as an officer of the company, filed an initial Form 3 statement of beneficial ownership. The filing states that, as of the reported event date, the officer has no securities beneficially owned in LB Pharmaceuticals. This establishes that the executive currently holds no direct or indirect ownership in the company’s securities under the relevant reporting rules.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pai Panandiker Kaya Kamlesh

(Last) (First) (Middle)

C/O LB PHARMACEUTICALS INC

ONE PENNSYLVANIA PLAZA, SUITE 1025

(Street)

NEW YORK NY 10119

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/10/2025

3. Issuer Name and Ticker or Trading Symbol
LB PHARMACEUTICALS INC [ LBRX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Marc Panoff, Attorney-in-Fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the LB Pharmaceuticals (LBRX) Form 3 filing report?

The Form 3 for LB Pharmaceuticals Inc. (LBRX) reports that the company’s Chief Commercial Officer has no securities beneficially owned in the issuer.

Who is the reporting person in the LB Pharmaceuticals (LBRX) Form 3?

The reporting person is an officer of LB Pharmaceuticals Inc. (LBRX), serving as the company’s Chief Commercial Officer.

Does the LB Pharmaceuticals Chief Commercial Officer own LBRX shares?

According to the Form 3, the Chief Commercial Officer of LB Pharmaceuticals Inc. has no securities beneficially owned in LBRX.

Is this LB Pharmaceuticals (LBRX) Form 3 filed by more than one reporting person?

No. The Form 3 indicates it is filed by one reporting person, not by a group.

What type of securities are covered in the LB Pharmaceuticals (LBRX) Form 3?

The Form 3 includes sections for both non-derivative and derivative securities, but the explanation of responses states that no securities are beneficially owned.